NasdaqCM - Nasdaq Real Time Price USD

KALA BIO, Inc. (KALA)

0.1655 -0.0096 (-5.48%)

At close: October 30 at 4:00:00 PM EDT

0.1763 +0.0108 (+6.53%)

After hours: October 30 at 7:58:54 PM EDT

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for KALA

1h ago Powered by Yahoo Scout

KALA BIO is expanding beyond its biologics pipeline through genetic testing, telehealth, and artificial-intelligence infrastructure initiatives. The newest development is a proposed $15 million acquisitionof a telehealth platform, while the company’s latest reported regular-session move was down 5.48% on November 1, 2026.

Previous Close 0.1751
Open 0.1750
Bid 0.1731 x 100
Ask 0.2740 x 100
Day's Range 0.1630 - 0.1832
52 Week Range 0.1150 - 95.5000
Volume 232,389
Avg. Volume 1,512,256
Market Cap (intraday) 3.201M
Beta (5Y Monthly) -2.41
PE Ratio (TTM) --
EPS (TTM) -10.7100
Earnings Date (est.) --
Forward Dividend & Yield -- (0.00%)
Ex-Dividend Date --
1y Target Est --

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

www.kalarx.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

KALA

99.40%

S&P 500 (^GSPC)

10.73%

1-Year Return

KALA

99.56%

S&P 500 (^GSPC)

11.11%

3-Year Return

KALA

99.95%

S&P 500 (^GSPC)

81.91%

5-Year Return

KALA

100.00%

S&P 500 (^GSPC)

64.59%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q3 FY25

Revenue --

Earnings -7.56M

Profit Margin 0.00%

FY24

FY25

-10M

-8M

-6M

-4M

-2M

0.0%

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-65.43%
Return on Equity (ttm)

-345.32%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-10.08M
Diluted EPS (ttm)

-10.7100

Balance Sheet and Cash Flow

Total Cash (mrq)

7.23M
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

-18.42M

CTMX

PALI

NERV

KPTI

ARDX

U.S. markets closed

KALA BIO, Inc. (KALA)

-12.89%

-61.42%

-96.85%

-99.40%

-99.56%

-100.00%

-100.00%

What's happening with KALA?

KALA BIO, Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch